Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.59
  • Today's Change-0.06 / -3.64%
  • Shares traded17.68k
  • 1 Year change-20.50%
  • Beta2.9797
Data delayed at least 15 minutes, as of Jul 11 2025 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

  • Revenue in USD (TTM)54.75m
  • Net income in USD-60.53m
  • Incorporated2000
  • Employees224.00
  • Location
    Cellectis SA8, rue de la Croix JarryPARIS 75013FranceFRA
  • Phone+33 181691600
  • Fax+33 181691606
  • Websitehttps://www.cellectis.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Tscan Therapeutics Inc4.42m-131.48m104.13m194.00--0.4954--23.55-1.09-1.090.03663.710.0154----22,788.66-45.85-38.91-51.34-43.93-----2,974.08-735.59----0.1328---86.62---42.91--25.13--
Contineum Therapeutics Inc0.00-49.83m104.26m41.00--0.5643-----1.93-1.930.007.140.00----0.00-30.97---32.50--------------0.00---100.00---285.99------
Cassava Sciences Inc0.00-72.79m104.35m30.00--0.8177-----1.51-1.510.002.640.00----0.00-49.07-28.22-70.57-29.72------------0.00------74.96--41.75--
Hillevax Inc0.00-106.50m105.30m14.00--0.6972-----2.16-2.160.003.010.00----0.00-43.20-60.41-46.23-88.64------------0.00-------19.18------
Coya Therapeutics Inc3.69m-17.14m105.79m8.00--3.17--28.71-1.07-1.070.23322.000.0972----460,637.50-45.21---51.05-------465.00------0.00---40.79---86.29------
Seres Therapeutics Inc0.00-66.86m107.85m103.00--2.14-----9.109.220.005.780.00----0.00-26.46-42.44-35.60-55.22-------367.23---228.600.00------33.85---17.63--
MDxHealth SA94.51m-38.77m107.90m312.00--18.08--1.14-1.08-1.082.340.12060.637311.286.70302,907.10-26.14-40.27-33.07-50.7561.9957.38-41.02-76.841.92-1.940.9337--28.2950.1911.67--96.87--
Biomea Fusion Inc0.00-128.63m110.05m79.00--2.52-----3.55-3.550.000.76490.00----0.00-115.08-62.24-144.14-68.84------------0.00-------18.06------
Tenaya Therapeutics Inc0.00-105.77m111.88m97.00--0.937-----1.16-1.160.000.7340.00----0.00-64.32-47.44-71.57-51.82------------0.00------10.44---18.92--
Cellectis SA (ADR)54.75m-60.53m112.35m224.00--1.03--2.05-0.6493-0.64930.57421.610.1524--4.58244,410.70-16.59-21.50-29.99-29.24---32.79-108.88-220.86---7.060.442--435.3716.4466.41---21.58--
Atossa Therapeutics Inc0.00-26.34m114.69m13.00--1.76-----0.2077-0.20770.000.50570.00----0.00-32.56-26.93-34.87-29.04------------0.00------15.25--20.02--
Achieve Life Sciences Inc0.00-46.16m115.77m25.00--7.86-----1.34-1.340.000.29640.00----0.00-94.80-95.73-132.48-142.31------------0.4894-------33.58------
TuHURA Biosciences Inc0.00-31.64m117.30m19.00--11.49-----4.10-4.100.000.22570.00----0.00-277.76---384.31-------------6.880.00--------------
Sangamo Therapeutics Inc63.76m-79.45m118.80m183.00--22.97--1.86-0.3464-0.34640.30060.02180.5927--120.64348,393.40-73.86-30.73-126.79-37.33-----124.61-147.59----0.00---67.20-10.8162.01---58.10--
Protara Therapeutics Inc0.00-45.42m120.38m28.00--0.7595-----1.71-1.710.004.110.00----0.00-38.37-35.06-40.52-36.43------------0.00-------10.33--31.54--
Actuate Therapeutics Inc0.00-25.31m121.25m6.00---------1.29-1.290.00-0.26050.00----0.00-704.75-----------------12.84---------10.27------
Data as of Jul 11 2025. Currency figures normalised to Cellectis SA's reporting currency: US Dollar USD

Institutional shareholders

18.60%Per cent of shares held by top holders
HolderShares% Held
Long Focus Capital Management LLCas of 31 Mar 20254.72m6.54%
The B Group, Inc.as of 31 Mar 20253.26m4.52%
UBS Asset Management Switzerland AGas of 31 Mar 20252.88m3.99%
UBS Asset Management (Americas) LLCas of 31 Mar 20251.85m2.56%
Macquarie Investment Management Business Trustas of 31 Mar 2025226.88k0.32%
Baillie Gifford & Co.as of 31 Mar 2025139.05k0.19%
Millennium Management LLCas of 31 Mar 2025103.85k0.14%
Jackson National Asset Management LLCas of 31 Mar 202588.67k0.12%
LPL Financial LLCas of 31 Mar 202584.75k0.12%
Morgan Stanley & Co. International Plcas of 31 Mar 202567.19k0.09%
More ▼
Data from 31 Mar 2025 - 31 Mar 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.